Effects of C7 substitutions in a high affinity microtubule-binding taxane on antitumor activity and drug transport.
暂无分享,去创建一个
I. Barasoain | Xi Xiao | Y. Li | F. Sharom | Hui Chen | L. Sheng | C. Trigili | Ying Zhao | P. Lu | W. Fang | J. Díaz | J. Chu | Julian Wu
[1] J. Trojanowski,et al. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies , 2009, Nature Reviews Drug Discovery.
[2] F. Sharom,et al. ABC efflux pump-based resistance to chemotherapy drugs. , 2009, Chemical reviews.
[3] R. Himes,et al. Paclitaxel succinate analogs: Anionic and amide introduction as a strategy to impart blood-brain barrier permeability. , 2008, Bioorganic & medicinal chemistry letters.
[4] Xiaoguang Chen,et al. Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo. , 2008, Cancer letters.
[5] Federico Gago,et al. Optimization of taxane binding to microtubules: binding affinity dissection and incremental construction of a high-affinity analog of paclitaxel. , 2008, Chemistry & biology.
[6] G. Scambia,et al. New taxanes in development , 2008 .
[7] M. Botta,et al. Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes , 2007, ChemMedChem.
[8] I. Barasoain,et al. Overcoming Tumor Drug Resistance with High‐Affinity Taxanes: A SAR Study of C2‐Modified 7‐Acyl‐10‐Deacetyl Cephalomannines , 2007, ChemMedChem.
[9] E. Rowinsky,et al. Novel agents that target tublin and related elements. , 2006, Seminars in oncology.
[10] R. Himes,et al. Single-site chemical modification at C10 of the baccatin III core of paclitaxel and Taxol C reduces P-glycoprotein interactions in bovine brain microvessel endothelial cells. , 2006, Bioorganic & medicinal chemistry letters.
[11] R. Himes,et al. Synthesis and interactions of 7-deoxy-, 10-deacetoxy, and 10-deacetoxy-7-deoxypaclitaxel with NCI/ADR-RES cancer cells and bovine brain microvessel endothelial cells. , 2006, Bioorganic & medicinal chemistry letters.
[12] R. Himes,et al. Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ. , 2005, Journal of medicinal chemistry.
[13] Susan Band Horwitz,et al. Mechanisms of Taxol resistance related to microtubules , 2003, Oncogene.
[14] C. Decker,et al. Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. , 2001, Current opinion in chemical biology.
[15] G Beck,et al. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. , 2001, Journal of pharmaceutical sciences.
[16] M. Zucchetti,et al. IDN5109, a taxane with oral bioavailability and potent antitumor activity. , 2000, Cancer research.
[17] R. Himes,et al. THE CHEMISTRY OF THE TAXANE DITERPENE : STEREOSELECTIVE REDUCTIONS OF TAXANES , 1998 .
[18] P. Giannakakou,et al. Synthesis and biological evaluation of 2-acyl analogues of paclitaxel (Taxol). , 1998, Journal of medicinal chemistry.
[19] M. Yazdanian,et al. Correlating Partitioning and Caco-2 Cell Permeability of Structurally Diverse Small Molecular Weight Compounds , 1998, Pharmaceutical Research.
[20] Zhuming Zhang,et al. Selective protection of the C(7) and C(10) hydroxyl groups in 10-deacetyl baccatin III , 1998 .
[21] J. Díaz,et al. Characterizing ligand-microtubule binding by competition methods. , 2007, Methods in molecular medicine.
[22] W. Fang,et al. Recent progress in structure activity relationship and mechanistic studies of taxol analogues. , 2005, Mini reviews in medicinal chemistry.